secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001104659-25-098994
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma doses first subject in Phase 2 COVID study of ratutrelvir; top-line data by year-end 2025
--------------------------------------------------------------------------------

- First subject dosed in Phase 2 study of ratutrelvir, a ritonavir-free anti-viral for newly diagnosed COVID.
- Two trials: non-inferiority versus PAXLOVID and a single-arm study for PAXLOVID-ineligible patients.
- Top-line results from both Phase 2 studies expected by year-end 2025.
- Ratutrelvir is once-daily, single tablet for 10 days; aims to reduce rebound and Long COVID risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925098994/0001104659-25-098994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925098994/tm2528641d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-098994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer